DocGo Inc. (DCGO) Q3 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presents a mixed outlook. While debt reduction and cash flow improvements are positive, declining margins and lack of specific guidance on SG&A reductions and EBITDA improvements raise concerns. The Q&A reveals uncertainties, especially in margin improvements and future contracts. However, the company is debt-free and expects cash flow to improve, balancing the negatives. Without a market cap, the neutral rating reflects the mixed signals and potential for both positive and negative reactions, suggesting a stock price movement between -2% and 2%.

Key Financial Performance

Total Revenue (Q3 2025) $70.8 million, compared to $138.7 million in Q3 2024. The year-over-year decline was due to the sunset of migrant-related projects. Excluding migrant-related programs, revenue increased by 8% to $62.4 million from $58 million in Q3 2024.

Medical Transportation Revenue (Q3 2025) $50.1 million, up from $48 million in Q3 2024. Growth was driven by gains in nearly all U.S. markets, especially Texas and Tennessee.

Mobile Health Revenue (Q3 2025) $20.7 million, down from $90.7 million in Q3 2024, due to the wind down of migrant services. Non-migrant Mobile Health revenues increased by more than 20% year-over-year, driven by Care Gap Closures, Remote Patient Monitoring, and Mobile Phlebotomy.

Adjusted EBITDA (Q3 2025) Loss of $7.1 million, compared to a gain of $17.9 million in Q3 2024. The decline was attributed to the sunset of migrant-related projects and investments in Care Gap Closure business.

Adjusted Gross Margin (Q3 2025) 33%, compared to 36% in Q3 2024. Medical Transportation segment margins improved to 31.7% from 30.7%, while Mobile Health segment margins declined to 36.2% from 38.8%.

Cash and Cash Equivalents (End of Q3 2025) $95.2 million, down from $107.3 million at the beginning of the year. However, the company paid off $30 million in debt, leaving it debt-free for the first time since late 2023.

Accounts Receivable (Migrant Programs) $37 million at the end of Q3 2025, down from $54 million at the end of Q2 2025 and $150 million at the end of 2024. Approximately 96% of all migrant-related receivables have been collected.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

Acquisition of SteadyMD: DocGo acquired SteadyMD, a virtual care provider with a 50-state network and over 500 advanced practice providers. This acquisition is expected to enhance operational efficiency and scale.

Remote Patient Monitoring: This business is operating at an annual run rate of $15 million with a greater than 10% adjusted EBITDA contribution margin, expected to grow in 2026.

Primary Care Services: Progress is being made with a major health plan to offer services to 10,000 members, launching in Q4 2025 and ramping in 2026.

Medical Transportation Business: Achieved record volumes in Q3 2025, expected to generate over $200 million in revenue for 2025. Plans to hire additional EMS staff to capture millions in additional revenue in 2026.

Payer and Provider Vertical: Expected to grow from $50 million in 2025 to $85 million in 2026, driven by services like Care Gap Closure, Telehealth, and Mobile Phlebotomy.

Adjusted EBITDA: DocGo reported an adjusted EBITDA loss of $7.1 million in Q3 2025, with plans to improve margins and achieve profitability by the end of 2026.

Cash Position: The company is now debt-free, with $95.2 million in cash and cash equivalents as of Q3 2025.

Transition to Long-Term Healthcare Solutions: DocGo is shifting focus from emergency response contracts to integrated, technology-driven healthcare solutions.

Investment in Care Gap Closure and Primary Care: Significant investments in these areas are expected to decline in 2026, contributing to profitability.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Revenue Decline: The company experienced a significant year-over-year revenue decline in Q3 2025, primarily due to the sunset of migrant-related projects. This decline has impacted overall financial performance.

Adjusted EBITDA Loss: The company reported an adjusted EBITDA loss of $7.1 million in Q3 2025, compared to a positive $17.9 million in Q3 2024. This reflects operational and financial challenges.

Labor Shortages: The Medical Transportation business is facing labor shortages, requiring the hiring of hundreds of additional EMS staff to meet demand and capture potential revenue.

Care Gap Closure and Primary Care Profitability: The Care Gap Closure and Primary Care services are not yet profitable, requiring substantial investment in product development, training, and technology. This is delaying profitability in these segments.

Insurance Costs: The company incurred increased insurance costs of approximately $5.2 million, including premiums for workers' compensation and settlement of a large auto insurance claim.

Intangible Asset Write-Downs: Noncash charges due to the write-down of intangible assets and goodwill totaled $16.7 million in Q3 2025, negatively impacting financial results.

Migrant-Related Receivables: The company still has $37 million in accounts receivable from migrant-related programs, which could pose collection risks despite progress in reducing these receivables.

High Investment in Early-Stage Business Lines: Significant investments in early-stage business lines, such as Care Gap Closure and Primary Care, are straining financial resources and delaying profitability.

Dependency on New Contracts and Acquisitions: Future revenue growth and profitability are heavily dependent on securing new contracts and successful integration of acquisitions like SteadyMD.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

2026 Revenue Guidance: The company announced 2026 revenue guidance of $280 million to $300 million, representing 12% to 20% year-over-year base business growth. Any potential acquisitions or new contract wins would be incremental to this amount.

2026 Adjusted EBITDA Guidance: The company expects a full-year 2026 adjusted EBITDA loss of $15 million to $25 million, with the majority of this loss expected in the first half of the year. At the top end of the revenue guidance range, the company anticipates exiting 2026 on an adjusted EBITDA positive run rate.

Medical Transportation Business Outlook: The Medical Transportation business is expected to generate more than $200 million in revenue in 2025. Over the next 2 to 3 years, the company anticipates improving the adjusted EBITDA contribution margin to approximately 12% as additional scale and staffing are added.

Payer and Provider Vertical Growth: This vertical is expected to grow from $50 million in 2025 to $85 million in 2026. Remote patient monitoring is operating at an annual run rate of approximately $15 million with a greater than 10% adjusted EBITDA contribution margin, which is expected to trend higher in 2026.

Primary Care Services Ramp-Up: The company expects progress in primary care services, with a substantial list from a major health plan to offer services to 10,000 members launching in Q4 2025 and ramping in early 2026.

Care Gap Closure and Transitions of Care Business: The company expects the rate of investment in this business to decline considerably in 2026, contributing to the goal of achieving profitability.

SteadyMD Acquisition Impact: The acquisition of SteadyMD is expected to enable more efficient delivery of patient care and create synergies with DocGo's offerings. SteadyMD is projected to generate approximately $25 million in revenue in 2025 and service over 3 million patients.

2025 Revenue and Adjusted EBITDA Outlook: For full-year 2025, the company expects revenues in the range of $315 million to $320 million, with adjusted EBITDA loss in the range of $25 million to $28 million.

2026 Sequential Performance: The company expects revenues to increase and EBITDA performance to improve sequentially over each of the four quarters of 2026.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:Looking at the implied margins for the fourth quarter, which appear to be around negative 13%, can you help bridge us versus margins we saw in the third quarter of down 10%? How much came from SteadyMD acquisition versus core operations?

A:SteadyMD showed up in October and will contribute around $5 million in revenue for the quarter, being slightly EBITDA negative. It will impact the margin percentage but not materially affect overall margins. Additionally, there will be very small revenue from migrant-related sources, which will also impact margins slightly.

Q:For 2026 EBITDA guidance, the implied margins are negative 10%. Yet we're exiting the fourth quarter at negative 13% margin. Can you walk us through how that improves throughout the year?

A:The improvement will come from better gross margins, especially from transport projects, and reduced SG&A expenses. Revenue is expected to be lowest in Q1 2026 and improve each quarter. EBITDA losses will be skewed towards the first half of the year, with smaller losses in Q3 and potentially a positive number in Q4.

Q:For 2026 revenue guidance, how much do you assume for migrants next year? How should we model transport versus Mobile Health next year?

A:There will be no migrant-related revenues for 2026. The revenue breakdown is expected to be about 2/3 Transport and 1/3 Mobile Health.

Q:For Payer-Provider revenue growth, stepping up from $50 million in 2025 to $85 million in 2026, does $15 million come from SteadyMD and $20 million from organic growth? What deal closure assumptions are included?

A:The $85 million includes $25 million from SteadyMD and $60 million from the current Payer-Provider baseline business. It does not include any deal closures, additional M&A, or contributions from the pipeline.

Q:What does it look like when you expand Payer-Provider contracts from Transition of Care to Care Gap Closure to Longitudinal? How does it impact revenue or margins?

A:Contracts typically start with Care Gap Closure or Transitional Care Management and expand into primary and preventative care, leading to larger patient lists and more varied needs. This progression improves patient outcomes and reduces costs for payers, which can positively impact revenue and margins.

Q:On the transportation side, how do you balance supply/demand to ensure scaling the team is not margin dilutive?

A:The company is addressing the 26,000 trips outsourced over the last 12 months by hiring 700-800 staff to meet this embedded demand. Hiring plans are based on quantifying trips and corresponding staff needs.

Q:What are the core areas of focus for remote patient monitoring (RPM), and does recent news about United rolling back RPM coverage impact the market?

A:The core focus for RPM is in cardiology, particularly chronic heart failure and implantable cardiac devices. The rollback by United to focus on cardiology aligns with the company's expertise and is not expected to negatively impact the market.

Q:What is your current view of the hospital and hospital spending environment? Have you heard any concerns from customers?

A:Hospitals are cautious due to uncertainty around ACA and Medicaid, but the company focuses on saving hospitals money and improving efficiency. Recent conversations with hospital systems indicate interest in outsourcing patient flow management to reduce costs.

Q:Have you seen any impact from the government shutdown on municipal decision-making?

A:The company has shifted focus away from population government work to hospital systems, payers, and providers. It is too early to see any impact from the government shutdown.

Q:How were bookings in the third quarter, and how much did they grow sequentially?

A:Sequential growth was seen across all business lines, with mid-single-digit growth in U.S. transport trip counts. Q3 volumes were record-high across all business lines.

Q:How much cash do you expect to have at the end of the year?

A:The company expects cash to increase slightly from the Q3 level of $95 million (including restricted cash) by the end of Q4, with a projected exit of 2026 at $65 million or higher.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details on how much SG&A reductions would contribute to margin improvements or the exact timeline for achieving positive EBITDA in Q4 2026. Additionally, they did not elaborate on the potential impact of new contracts or M&A on future guidance.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

DCGO Transcript

DocGo Inc. (DCGO) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Neutral12-9

DocGo Inc. (DCGO) Q3 2025 Earnings Call Transcript

Unknown11-10

DocGo Inc. (DCGO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Neutral9-10

DocGo Inc. (DCGO) Q2 2025 Earnings Call Transcript

Unknown8-8

The earnings call reveals several concerning factors: a substantial revenue decline, a widened adjusted EBITDA loss, and a significant reduction in revenue guidance. Despite a stock buyback program and improved cash flow, the company's financial health is challenged by reduced margins and increased costs. The Q&A section highlights operational inefficiencies and management's vague responses, further dampening sentiment. These factors, combined with strategic and execution risks, suggest a negative stock price reaction, likely between -2% to -8%.

DCGO Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.